富马酸伏诺拉生联合阿莫西林治疗幽门螺杆菌感染的临床效果  

Clinical effect of vonoprazan fumarate combined with amoxicillin in the treatment of Helicobacter pylori infection

作　　者：武善霞 刘洋 WU Shanxia;LIU Yang(Department of Pharmacy,Linyi Central Hospital,Shandong Province,Linyi 276400,China)

机构地区：[1]山东省临沂市中心医院药学部,276400

出　　处：《临床合理用药》2025年第2期4-7,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察富马酸伏诺拉生联合阿莫西林治疗幽门螺杆菌感染的临床效果。方法选取2023年1月—2024年1月临沂市中心医院收治的幽门螺杆菌感染患者62例,采用随机数字表法分为研究组和对照组,每组31例。对照组采用常规四联疗法治疗,研究组采用富马酸伏诺拉生联合阿莫西林治疗,2组均治疗1个月。比较2组临床疗效,治疗前后症状积分、炎性指标[白介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、C反应蛋白(CRP)]水平,幽门螺杆菌根除率、复发率及不良反应。结果研究组总有效率(96.77%)高于对照组(80.65%)(χ^(2)=4.026,P=0.045)。治疗1个月后,2组上腹痛、反酸嗳气、恶心呕吐积分均低于治疗前,且研究组低于对照组(P<0.05或P<0.01);2组IL-2、TNF-α、IL-6及CRP水平均低于治疗前,且研究组低于对照组(P<0.01)。研究组幽门螺杆菌根除率为96.77%(30/31),高于对照组的80.65%(25/31)(χ^(2)=4.026,P=0.045);研究组疾病复发率为3.33%(1/30),低于对照组的28.00%(7/25)(χ^(2)=4.838,P=0.028)。研究组不良反应总发生率(3.23%)低于对照组(19.35%)(χ^(2)=4.026,P=0.045)。结论富马酸伏诺拉生联合阿莫西林治疗幽门螺杆菌感染的疗效较好,安全性较高,可改善患者症状,降低血清炎性指标,提升幽门螺杆菌根除率,降低疾病复发率。Objective To observe the clinical effect of vonoprazan fumarate combined with amoxicillin in the treatment of Helicobacter pylori infection.Methods A total of 62 Helicobacter pylori infected patients admitted to Linyi Central Hospital from January 2023 to January 2024 were selected and divided into study group and control group by random number table method,with 31 cases in each group.The control group was treated with conventional quadruple therapy,and the study group was treated with vonoprazan fumarate combined with amoxicillin.Both groups were treated for 1 month.The clinical efficacy,symptom scores and inflammatory indexes(IL-2,TNF-α,IL-6,CRP)levels before and after treatment,eradication rate of Helicobacter pylori,recurrence rate and adverse reactions of two groups were compared.Results The total effective rate of the study group(96.77%)was higher than that of the control group(80.65%)(χ^(2)=4.026,P=0.045).After 1 month of treatment,the scores of epigastric pain and regurgitation,nausea and vomiting in two groups were lower than before treatment,and those in the study group were lower than those in the control group(P<0.05 or P<0.01).The levels of IL-2,TNF-α,IL-6 and CRP in two groups were lower than before treatment,and the levels in study group were lower than those in control group(P<0.01).The eradication rate of Helicobacter pylori the research group was 96.77%,which was higher than that in the control group(80.65%)(χ^(2)=4.026,P=0.045).The recurrence rate of the study group was 3.33%,which was lower than that of the control group(28.00%)(χ^(2)=4.838,P=0.028).The total incidence of adverse reactions in the study group(3.23%)was lower than that in the control group(19.35%)(χ^(2)=4.026,P=0.045).Conclusion The combination of vonoprazan fumarate and amoxicillin in the treatment of Helicobacter pylori infection has good efficacy and high safety,which can improve the symptoms of patients,reduce serum inflammatory indexes,increase the eradication rate of Helicobacter pylori,and reduce the recurrence rate

关 键 词：幽门螺杆菌感染 富马酸伏诺拉生 阿莫西林 临床疗效 症状积分 炎性指标 幽门螺杆菌根除率 不良反应 

分 类 号：R573[医药卫生—消化系统]